Appropriate patient selection for biologic therapy to treat IBD is crucial - selecting between different agents for first-line therapy, managing intolerance or safety issues, and switching agents in patients who do not respond or lose their initial response to therapy pose key concerns. This practice pointer provides some guidance regarding when to consider starting therapy with a biologic, and also gives some "tips and pointers" regarding which therapy to select and if this should be monotherapy or combination therapy.
This activity has been designed to meet the educational needs of gastroenterologists and registered nurses involved in the care of patients with inflammatory bowel disease (IBD).
Release date: June 24, 2016
Expiry date: June 24, 2017
After completing this activity, the participant should be better able to:
Professor of Medicine
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Name of Faculty or Presenter
Reported Financial Relationship
Gary R. Lichtenstein
Advisor or consultant for: Abbott Laboratories, Centocor Ortho Biotech Inc., Elan Pharmaceuticals, Inc., Ferring Pharmaceuticals, Genentech, Inc., Meda Pharmaceuticals, Inc., Merck & Co., Inc., Millennium Pharmaceuticals, Inc., Pfizer Inc., Procter & Gamble, Prometheus Laboratories Inc., Salix Pharmaceuticals, Inc., Santarus, Inc., Schering-Plough Corporation, Shire, Therakos, Inc., UCB Pharma, Inc., Warner Chilcott, Wyeth Pharmaceuticals Inc.
Received grants for clinical research from: Bristol-Myers Squibb, Centocor Ortho Biotech Inc., Ferring Pharmaceuticals, Meda Pharmaceuticals, Inc., Procter & Gamble, Prometheus Laboratories Inc., Salix Pharmaceuticals, Inc., Shire, Therakos, Inc., UCB Pharma, Inc., Warner Chilcott
The planners and managers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:
The following PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, RN, BSN, and Jan Schultz, RN, MSN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
The following SCI planners and managers, Ian Morgan, MSc, and Elena Urso, BSc, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity or any amount during the past 12 months.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Strategic Consultants International. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This educational activity for 0.7 contact hours is provided by Postgraduate Institute for Medicine.
Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
Estimated time to complete activity: 45 minutes
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
There are no fees for participating and receiving CME/CE credit for this activity.
To successfully earn credit, participants must complete the activity online during the valid credit period.
Follow these steps to earn CME/CE credit:
Upon successful completion of the posttest, with a passing score of 75% or better, and the online Evaluation form, you will have immediate access to a CME/CE certificate to print or save for your files. We strongly encourage you to complete the Activity Evaluation to provide your feedback for future programming.
If you have any questions regarding the CME/CE certification for this activity, please contact Postgraduate Institute for Medicine at: email@example.com or (303) 799-1930.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
All website content copyright Inflammatory Bowel Disease Working Group.